BioSpring is the first third-party formula manufacturing pharmaceutical company in Laos to expand the global market Long-term development goals include serving Southeast Asia, South Asia, Arabia, Eastern Europe, Central Asia, West Asia, Africa, Latin America and other markets Planned product lines include epidemiological drugs, oncology drugs, rare disease drugs, and long-term care and companion animal drugs June 14, 2022, Vientiane, Laos–BioSpring…
BioSpring will acquire all formulations, processes and equipment for SAILIN's anticancer drug product line. BioSpring's acquisition of SAILIN includes its brand, but BioSpring does not operate its brand. All acquisitions are expected to be completed by the end of this year. July 27, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") announces Acquisition of Laos Anticancer Drug Company Sailin biopharma. The acquisition…
August 18, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") announces Phase 1 of the manufacturing unit was constructed and delivered. This time, the delivery of the manufacturing unit constructed according to the ICH1-GMP2 standard is the first step for BioSpring to serve global users. With the strong support and joint efforts of the Vientiane government of Laos and the Saysettha Comprehensive Development Zone,…
September 07, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") announces coommerical packaging solutions for formulation manufacturing. Completing the prefabrication process for this commercial package ahead of time will help shorten the overall manufacturing cycle. Samuel, founder and CEO of BioSpring, said: “BioSpring can help customers overcome the challenges of formulating, processing and scaling up manufacturing of generic drugs.” Days it takes…
September 08, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching Tadazen (tadalafil) tablet for customers, which will be available in a single strength of 20mg, and each box of tadazen includes 8 tablets.It is a tablet taken by mouth. Onset is typically within half an hour and the duration is up to 36 hours. This product is manufactured and produced by…
September 14, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") launches New Product Packaging for SaiLin's Global Market Customers. This product packaging upgrade is to fulfill the previous promise of BioSpring's acquisition of SaiLin, and will continue to provide follow-up support and services to Sailin's global customers. The batch will use Biospring's anti-counterfeiting verification system. Including the following 7 anticancer drug…
September 20, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching Bioscovy (emtricitabine 200mg/ tenofovir alafenamide 25mg) tablet for customers, each box of Bioscovy includes 30 tablets. It is a tablet taken by mouth. Bioscovy for PrEP (pre-exposure prophylaxis) is a once-daily prescription medicine for adults and adolescents at risk of HIV. Bioscovy for PrEP is not for everyone: It is not…
October 05, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOPALB (Palbociclib 125mg) capsules are indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (mBC) in combination with: an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men, or fulvestrant in patients…
October 06, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIODEUCRA (Deucravacitinib 6mg) tablets for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the first approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis…
October,24,2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") that it has reached preliminary cooperation intentions with clients at the "Medlab Asia & Asia Health 2022" event in Bangkok. At the event site, BioSpring's business team communicated and communicated with customers from Nepal, Bhutan, and Timor-Leste, and the two parties reached preliminary intentions on business cooperation and product registration submissions. The client…
November 07, 2022, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching BIOMOB (Mobocertinib 40mg) capsules for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) mutation. Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region.Mobocertinib is an irreversible kinase inhibitor, forming a covalent…
January 10, 2023, Vientiane, Laos--BioSpring ("BioSpring Group.LTD" "BioSpring Group") is launching Generic (Molnupiravir 200mg) capsules & Generic 150mg Nirmatrelvir/ 100mg Ritonavir tablets KIT for the treatment of Covid-19 virus infection. Molnupiravir is an antiviral medication that inhibits the replication of certain RNA viruses. It is used to treat COVID-19 in those infected by SARS-CoV-2. It is taken by mouth.The Generic…
